logo-loader
NASDAQ:PDSB

PDS Biotechnology Corporation

Receive alerts
Market:
NASDAQ
Market Cap:
$19.2 m
Price
1.25 USD
Change
-4.58%
52 weeks high
7.16
52 weeks low
0.62

In brief

PDS Biotechnology is a clinical-stage immuno-oncology company with a broad pipeline of novel products based on the company’s proprietary Versamune® T-cell activating technology.  The Versamune® platform effectively delivers tumor-specific antigens for in-vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent tumor-specific killer T-cells.  Using Versamune®, PDS Biotechnology is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors.  PDS Biotechnology’s pipeline combines the Versamune® technology with tumor-specific antigens across several cancer types.